蔡挺，男，博士，江苏省****，博士生导师，江苏省****基金获得者，现任中国药科大学科技处副处长，校侨联副主席。2003年本科毕业于复旦大学化学系，2008年博士毕业于美国弗吉尼亚理工大学化学系，随后在美国威斯康辛大学麦迪逊分校药学院从事药剂学博士后研究工作。2014年回国工作前在美国上市制药公司药物制剂部担任研究员，工作期间主持和完成多项难溶性药物复杂制剂的研发工作。主要研究方向为物理药剂学、工业药剂学、药物晶体学、创新药物剂型设计、药物体内过程评价和制剂工程等，已在J. Am. Chem. Soc.、ACS Appl. Mater. Interfaces、Chem. Commun.、Mol Pharmaceutics、Cryst. Growth Des.等化学和药学知名期刊发表论文50余篇，引用1000多次。作为项目负责人主持国家“十三五”新药创制重大专项、国家自然科学基金面上项目等多项国家和企业合作课题；作为领军人才主持江苏省“双创计划”创新团队项目并入选江苏省“六大人才高峰计划”；获得2015年中国药物制剂大会“青年药剂学奖”；目前担任药剂学杂志Journal of Pharmaceutical Sciences科学顾问，Asian Journal of Pharmaceutical Sciences和《药学进展》的青年编委。目前担任江苏省生物技术协会青年专委会主任委员，中国晶体协会药物晶体学专业委员会委员，中国颗粒学会青年理事会理事，中国药学会药剂专委会青年委员，中华中医药学会中药制药工程分会委员。
课题组围绕物理药剂学和制剂工程学领域的前沿科学问题，利用先进的理化技术手段，开展理论和应用研究工作。主要研究内容包括:
（1）药物晶型、结晶工艺及粉体学研究
（2）难溶性药物的固体分散体制剂研究
（3）药物新型缓释及控释制剂
（4）药品质量控制和检测新技术
（5）药物新制剂与新技术
联系方式:tcai@cpu.edu.cn
近期和代表性论文：
Zhang, J.; Shi, Q.; Guo, M.; Liu, Z.; Cai, T.*“Melt Crystallization of Indomethacin Polymorphs in the Presence of Poly(ethylene oxide): Selective Enrichment of Polymer at the Crystal-Liquid Interface” Mol. Pharmaceutics2020, 17, 6, 2064–2071
Xu, J.; Huang, S.; Cai, T.*“Solvent-Induced, Highly Unusual, Triangular-Shaped Organic Polar Crystal”Cryst. Growth Des.2020, 20, 2527-2534
Shi, Q.; Tao, J.; Zhang, J.; Su, Y.; Cai, T.*“Crack- and Bubble-Induced Fast Crystal Growth of Amorphous Griseofulvin” Cryst. Growth Des. 2020, 20, 24-28
Moinuddin, S.; Shi. Q.; Tao, J.; Guo, M.; Zhang, J.; Xue,Q.; Ruan,S.;Cai, T.*“Enhanced Physical Stability and Synchronized Release of Febuxostat and Indomethacin in Coamorphous Solids” AAPS PharmSciTech202021, 41
Peng,Y.; Ye, C.;Yan, R.; Lei, Y.; Ye, D.; Hong, H.; Cai, T.*“Activatable Core?Shell Metallofullerene: An Efficient Nanoplatform for Bimodal Sensing of Glutathione” ACS Appl. Mater. Interfaces2019,11, 46637-46644
Huang, S.; Xu, J.; Peng, Y.; Guo, M.*; Cai, T.*“Facile Tuning of the Photoluminescence and Dissolution Properties of Phloretin through Cocrystallization” Cryst. Growth Des.2019,19, 6837-6844
Huang, S.; Xue, Q.; Xu, J.; Ruan,S.; Cai, T.*“Simultaneously Improving the Physicochemical Properties, Dissolution Performance, and Bioavailability of Apigenin and Daidzein by Co-Crystallization With Theophylline” Journal of Pharmaceutical Sciences2019, 108, 2982-2993
Xue, Q.; Ye C.; Zhang, M.; Hu, X.*; Cai, T.*“Glutathione responsive cubic gel particles cyclodextrin metal-organic frameworks for intracellular drug delivery”J. Colloid Interface Sci.2019, 551, 39-46.
Zhang, J.; Shi, Q.; Tao, J.; Peng, Y.; Cai, T.*“Impact of Polymer Enrichment at the Crystal?Liquid Interface on Crystallization Kinetics of Amorphous Solid Dispersions” Mol. Pharmaceutics2019,16, 1385-1396
Su, Y.; Yu, L.; Cai, T.*“Enhanced Crystal Nucleation in Glass-Forming Liquids by Tensile Fracture in the Glassy State”Cryst. Growth Des.2019,19, 40-44
Shi. Q.; Moinuddin, S. M.; Cai, T.*. Advances in coamorphous drug delivery systems”Acta Pharmaceutica Sinica B2019, 9, 19-35
Su Y.; Xu. J.; Shi. Q.; Yu L.;Cai, T.*“Polymorphism of Griseofulvin: Concomitant Crystallization from the Melt and Single Crystal Structure of a Metastable Polymorph with Anomalously Large Thermal Expansion”Chemical Communications,2018,54, 358-361.（X-MOL报道http://www.x-mol.com/news/11837）
Ruan, S.; Gu, Y.; Liu, B.; Gao, H.; Hu, X.; Hao, H.;* Jin, L.; *Cai, T.*“Long-Acting Release Microspheres Containing Novel GLP-1 Analog as an Antidiabetic System”Mol. Pharmaceutics 2018,15 , 2857-2869
Shi, Q.; Zhang, J.; Zhang, C.; Tao, J.; Jiang, J.; Zhou, D.;Cai, T.*“Selective Acceleration of Crystal Growth of Indomethacin Polymorphs by Low-Concentration Poly(ethylene oxide)”Mol. Pharmaceutics2017,14, 4694-4704.
Shi, Q.;Zhang, C.;Su, Y.;Zhang, J.;Zhou, D.*;Cai, T.*“Acceleration of Crystal Growth of Amorphous Griseofulvin by Low-Concentration Poly(ethylene oxide): Aspects of Crystallization Kinetics and Molecular Mobility”Mol. Pharmaceutics2017,14, 2262-2272.
Moinuddin, S. M.; Ruan, S.; Huang, Y.; Gao, Q.; Shi, Q.; Cai, B.;Cai, T.*“Facile Formation of Co-amorphous Atenolol and Hydrochlorothiazide Mixtures via Cryogenic-milling: Enhanced Physical Stability, Dissolution and Pharmacokinetic Profile”Int. J. Pharm.2017,532, 393-400.
Peng, Y.; Yang, D.; Lu, W.; Hu, X.; Hong, H.*;Cai, T.*“Positron Emission Tomography (PET) Guided Glioblastoma Targeting by a Fullerene-based Nanoplatform with Fast Renal Clearance”Acta Biomater.2017,61, 193-203.
Shi, Q.;Cai, T.*“Fast Crystal Growth of Amorphous Griseofulvin: Relations between Bulk and Surface Growth Modes”Cryst. Growth Des.2016, 16, 3279-3286
Xu, J.; Huang, Y.; Ruan, S.; Chi, Z.; Qin, K.; Cai, B.;* andCai, T*“Cocrystals of isoliquiritigenin with enhanced pharmacokineticperformance”CrystEngComm 2016, 18, 8776-8786
Cai, T.; Zhu, L.; Yu, L. “Crystallization of Organic Glasses: Effects of Polymer Additives on Bulk and Surface Crystal Growth in Amorphous Nifedipine”Pharm Res2011,28, 2458-2466
Cai, T.; Shu, C.; Xu, L.; Gibson, H. W.; Dorn, H. C. “Selective Formation of a Symmetric Bisadduct: Multi-Adduct Docking Controlled by an Internal Trimetallic Nitride Cluster”J. Am. Chem. Soc.2008,130, 2136-2137.
Cai, T.; Xu, L.; Gibson, H. W. ; Dorn, H. C.; Chancellor, C. J.; Olmstead, M. M.; Balch, A. L. “Sc₃N@C₇₈: Encapsulated Cluster Regio-Control of Adduct Docking on a Ellipsodal Metallofullerene Sphere”J. Am. Chem. Soc.2007,129,10795-10800.
Cai, T.; Slebodnick, C.; Xu, L.; Harich, K.; Glass, T.E.; Chancellor, C.; Fettinger, J. C.; Olmstead, M. M.; Balch, A. L.; Gibson, H. W.; Dorn, H. C. “A Pirouette on a Metallofullerene Sphere: Interconversion of Isomers of N-TritylpyrrolidinoI_hSc₃N@C₈₀”J. Am. Chem. Soc.2006,128, 6486-6492.
Cai, T.; Xu, L.; Anderson, M. R.; Ge, Z.; Zuo, T.; Wang, X.; Olmstead, M. M.; Balch, A. L.; Gibson, H. W.; Dorn, H. C. “Structure and Enhanced Reactivity Rates of the D_5hSc₃N@C₈₀and Lu₃N@C₈₀Metallofullerene Isomers: The Importance of the Pyracylene Motif”J. Am. Chem. Soc.2006,128, 8581-8589.
Cai, T.; Ge, Z.; Iezzi, E. B.; Glass, T. E.; Harich, K.; Gibson, H. W.; Dorn, H. C. “Synthesis and Characterization of the First Trimetallic Nitride Pyrrolidino Endohedral Metallofullerenes”Chem. Commun.2005,28, 3594-3596.